AMANITINKONJUGATE

European patent · EP3423104 · In force

Register entry

Publication number
EP3423104
Application number
EP17707350
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 2, 2017
Published
Jan 9, 2019
Granted
May 18, 2022
Protection ends at the latest
Mar 1, 2037
Next annual fee due
Mar 31, 2027
IPC classes
A61K 47/68 (2017.01)
A61P 35/02 (2006.01)
A61P 35/00 (2006.01)
Priority
EP 16000511 03.03.2016
PCT application
PCT/EP2017/054911 02.03.2017
PCT publication
WO2017/149077 08.09.2017
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  4. Apr 1, 2023

    Change

    Published in Swissreg on 01.04.2023

  5. Mar 29, 2023

    Change

    Published in Swissreg on 29.03.2023

  6. May 18, 2022

    Granted

    Published in Swissreg on 18.05.2022

Parties

Holder

Heidelberg Pharma Research GmbH

Gregor-Mendel-Straße 22, 68526 Ladenburg, DE

Inventor

HECHLER, Torsten

64686 Lautertal, DE

MÜLLER, Christoph

69488 Birkenau, DE

KULKE, Michael

67071 Ludwigshafen, DE

ANDERL, Jan

64397 Modautal, DE

SIMON, Werner

55595 Hüffelsheim, DE

LUTZ, Christian

69469 Weinheim, DE

WERNER-SIMON, Susanne

55595 Hüffelsheim, DE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.